DANA-FARBER CANCER INSTITUTE — History
CCN 220162 | 3-year financial timeline | COVID resilience: 83/100
🛡️ Public data only — no PHI permitted on this instance.
$1.9B
Latest Revenue (FY2022)
+21.2%
Revenue CAGR (3yr)
-35.1%
Financial Timeline
| Metric | FY2020 | FY2021 | FY2022 | YoY (Latest) | CAGR |
|---|---|---|---|---|---|
| Net Patient Revenue | $1.3B | $1.6B | $1.9B | +20.4% | +21.2% |
| Operating Expenses | $1.9B | $2.2B | $2.5B | +15.1% | +14.3% |
| Operating Margin | -51.8% | -41.4% | -35.1% | +15.2% | +0.0% |
| Net Income | $-664M | $-647M | $-660M | -2.1% | +0.0% |
| Licensed Beds | 30 | 30 | 30 | +0.0% | +0.0% |
| Total Patient Days | 9,385 | 10,059 | 9,609 | -4.5% | +1.2% |
| Medicare Day % | 36% | 35% | 35% | -0.3% | -1.4% |
| Medicaid Day % | 2% | 4% | 2% | -57.5% | -13.0% |
COVID Impact & Recovery
Resilience Score: 83/100 — Resilient — strong COVID recovery
Revenue recovery from FY2020 to FY2022: +46.9% ($1.3B → $1.9B)
FY2020 captured the initial COVID shock. Strong recovery indicates operational resilience and payer diversification.
Trend Summary
Revenue▲ Growing
Operating Margin▲ Growing
Beds▶ Stable
Medicare Mix▲ Growing
vs State Average ()
Revenue Growth
+21.2%
This Hospital
+7.6%
State Avg
Latest Margin
-35.1%
This Hospital
-4.6%
State Avg
Projections (FY2023-2025)
Extrapolated from 3-year trend using linear projection. Does not account for regulatory or market changes.
| Year | Revenue (proj) | Margin (proj) |
|---|---|---|
| FY2023 (proj) | $2.2B | -26.7% |
| FY2024 (proj) | $2.5B | -18.4% |
| FY2025 (proj) | $2.8B | -10.0% |